Previous 10 | Next 10 |
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it has achieved a major milestone with over 80 subjects in the QUILT-3.032 study completing at least 12 months of follow-up as of January 14, 2022. All data for QUILT-3.032, which is studying ...
BLA filing of Anktiva + BCG in BCG-unresponsive cancer in Situ non-muscle invasive bladder cancer patients is expected Q1 of 2022. Nant Cancer Vaccine combination with Anktiva, PD-L1 t-haNK, aldoxorubicin, low dose chemotherapy has established proof of concept in previously treated pa...
CytRx (OTCQB:CYTR) said it is absorbing its subsidiary Centurion BioPharma to bring efficiency and simplicity to its structure. Centurion's assets — which consists of LADR platform being developed for localized delivery of cancer therapeutics — will be taken over by the company ...
Natural killer (NK) cells play a critical role in the innate immune system’s ability to combat cancer, but the key to long-term treatment effectiveness is ensuring their persistence A Washington University School of Medicine study shows that increasing NK cell persistence a...
Gainers: Renewable Energy Group REGI +34%. Golden Entertainment (NASDAQ:GDEN) +17%. Homology Medicines (NASDAQ:FIXX) +7%. Cara Therapeutics CARA +5%. Arcimoto (NASDAQ:FUV) +5%. Losers: Fate Therapeutics (NASDAQ:FATE) -5%. CSP (NASDAQ:CSPI) -3%. ImmunityBio (NAS...
Palm Beach, FL – February 16, 2022 – FinancialNewsMedia.com News Commentary – The global blood testing market has grown during the pandemic and is expected to continue to rise in the coming years. Growing medical spending by the government and regulato...
Gainers: Brookdale Senior Living BKD +16%. American Shared Hospital Services AMS +12%. ImmunityBio IBRX +12%. I-Mab (NASDAQ:IMAB) +11%. Corvus Pharmaceuticals (NASDAQ:CRVS) +9%. Losers: Larimar Therapeutics LRMR -65%. Omnicell (NASDAQ:OMCL) -18%. M...
409,000 square foot, state-of-the-art facility expands capabilities for large-scale manufacture of vaccine and immunotherapy product candidates ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company (“ImmunityBio”), today announced the success...
BUFFALO, N.Y., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today the close of the sale of i...
ImmunityBio (NASDAQ:IBRX) is trading ~11% higher in the pre-market on Tuesday after reporting data from its late-stage bladder cancer trial (QUILT-3.032) for Anktiva (N-803), the company’s experimental cytokine infusion protein. In cohort A consisting of 83 patients with BCG-...
News, Short Squeeze, Breakout and More Instantly...
2024-07-27 01:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into ImmunityBio, Inc. (NasdaqGS: IBRX). On May 11, 2023, the Company disclosed that it had receiv...